“…9 Both the quantity and quality of influenza vaccination related information may negatively/positively affect immunization programs. 10,11 During the influenza season of 2014-2015, in Italy, in the week from 12 th to 18 th November 2014, three deaths occurred shortly after the administration of Fluad, an inactivated trivalent influenza vaccine, adjuvanted with an oil-in-water emulsion adjuvant (squalene, sodium citrate dihydrate, citric acid monohydrate, polysorbate 80, sorbitan trioleate, MF59C.1), manufactured in Italy by Novartis (Novartis Vaccines and Diagnostics, Inc., NVD), first approved for use in Europe in 1997 and authorized in a number of European Union countries, including Austria, Belgium, Germany, Denmark, Greece, Spain, France, Ireland, Luxembourg, Portugal, and Sweden, as well as in Italy. The first case occurred in a 68-year-old subject who died of myocardial infarction several hours following vaccination.…”